Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1370132
European Journal of Endocrinology, Vol 137, Issue 2, 132-137
Copyright © 1997 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Skjaerbaek, C
Right arrow Articles by Orskov, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Skjaerbaek, C
Right arrow Articles by Orskov, H

Clinical Studies

Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement

C Skjaerbaek, N Vahl, J Frystyk, TB Hansen, JO Jorgensen, C Hagen, JS Christiansen, and H Orskov

Institute of Experimental Clinical Research, Medical Research Laboratories, Aarhus University, Denmark.

The objective of the present study was to compare fasting levels of free IGF-I in serum from patients with adult onset growth hormone deficiency (GHD) and from healthy volunteers, and to examine the effect of GH replacement therapy in GHD on serum free IGF-I. Free IGF-I was measured using separation of free IGF-I by ultrafiltration in serum samples from 42 healthy volunteers and 27 patients with GHD, in the latter before and after 1 year of treatment with GH (2 IU/m2) (n = 13) or placebo (n = 14). Free IGF-I was significantly decreased in patients with GHD (700 +/- 100 ng/l (mean +/- S.E.M.), range 55-2618 ng/l) compared with controls (1010 +/- 70 ng/l, range 231-2431 ng/l; P = 0.0016). Total IGF-I was 85 +/- 10 micrograms/l (GHD) and 160 +/- 10 micrograms/l (controls) (P < 0.0001). The ratio of free over total IGF-I was increased in GHD to 0.85 +/- 0.08% compared with 0.66 +/- 0.05% in controls (P = 0.04). In both GHD and controls, free IGF-I correlated significantly (P < 0.05) with total IGF-I (GHD r = 0.78; controls r = 0.42), IGFBP-1 (GHD r = -0.67; controls r = -0.46) and the molar ratio of total IGF-I over IGFBP-3 (GHD r = 0.58; controls r = 0.62). After 1 year of GH treatment, free IGF-I was increased to 2780 +/- 320 ng/l (P = 0.003) and total IGF-I was increased to 270 +/- 30 micrograms/l (P = 0.006) both of which values were greater than those in healthy volunteers. There were no changes in free or total IGF-I in the placebo-treated group. In conclusion, levels of free IGF-I are decreased in GHD, but measurements of free IGF-I in a single, fasting serum sample do not offer a better separation of patients with GHD from individuals with normal GH status than can be achieved by measurement of total IGF-I. One year of treatment with 2IU/m2 GH caused an increase of serum free IGF-I to supraphysiological levels.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
P. Marzullo, C. Di Somma, K. L. Pratt, J. Khosravi, A. Diamandis, G. Lombardi, A. Colao, and R. G. Rosenfeld
Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3001 - 3008.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen
Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids
Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Dall, S. Longobardi, C. Ehrnborg, N. Keay, T. Rosén, J. O. L. Jørgensen, R. C. Cuneo, M. A. Boroujerdi, A. Cittadini, R. Napoli, et al.
The Effect of Four Weeks of Supraphysiological Growth Hormone Administration on the Insulin-Like Growth Factor Axis in Women and Men
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4193 - 4200.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
N. Kawai, S. Kanzaki, S. Takano-Watou, C. Tada, Y. Yamanaka, T. Miyata, M. Oka, and Y. Seino
Serum Free Insulin-Like Growth Factor I (IGF-I), Total IGF-I, and IGF-Binding Protein-3 Concentrations in Normal Children and Children with Growth Hormone Deficiency
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 82 - 89.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
I. M. Chapman, M. L. Hartman, K. S. Pieper, E. H. Skiles, S. S. Pezzoli, R. L. Hintz, and M. O. Thorner
Recovery of Growth Hormone Release from Suppression by Exogenous Insulin-Like Growth Factor I (IGF-I): Evidence for a Suppressive Action of Free Rather Than Bound IGF-I
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2836 - 2842.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
C. Skjærbæk, J. Frystyk, H. Ørskov, P. Kissmeyer-Nielsen, M. B. Jensen, S. Laurberg, N. Møller, and A. Flyvbjerg
Differential Changes in Free and Total Insulin-Like Growth Factor I after Major, Elective Abdominal Surgery: The Possible Role of Insulin-Like Growth Factor-Binding Protein-3 Proteolysis
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2445 - 2449.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 European Society of Endocrinology.